Connect your AI

Celldex Therapeutics CLDX Price / book

Price / book at other companies

Eli LillyLLY

26.3×-20.7×

PfizerPFE

1.8×+0.2×

Rogers CorporationROG

1.6×+0.6×

AmgenAMGN

20.6×-6.3×

Regeneron PharmaceuticalsREGN

2.6×+0.2×

IncyteINCY

3.3×+0.1×

Other financials

Income statement

Revenue$15.0K-97.8%

Operating income-$84.4M-34.6%

Net income-$78.7M-46.3%

EPS (diluted)-$1.18-45.7%

Balance sheet

Cash & equivalents$35.7M+109%

Total debt$1.9M-44.3%

Total equity$456.2M-35.1%

Total assets$511.3M-30.9%

Cash flow

Operating cash flow-$65.6M-20.6%

CapEx$1.6M+518%

Free cash flow-$67.2M-23.0%

Valuation

Market cap$2.59B+75.2%

Enterprise value$2.55B+74.4%

P/S2,989.2×+2,794×

Profitability

Operating margin-35,688.5%-39,114pp

Net margin-32,753.6%-35,519pp

FCF margin-26,125.8%-28,907pp

Returns & leverage

Return on equity-48.9%-498pp

Debt / equity0×0.0×

Current ratio8.9×-12.7×

Where this comes from

Calculated from Celldex Therapeutics’s reported figures.

market cap/total stockholders equity=4.6×

Based on the most recent quarter.

The official record: Celldex Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Celldex Therapeutics's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Celldex Therapeutics's price / book?: Celldex Therapeutics (CLDX) reported price / book of 4.6× in Q1 2026.
How has Celldex Therapeutics's price / book changed year-over-year?: Celldex Therapeutics's price / book increased by 170.0% year-over-year, from 1.7× to 4.6×.
What is the long-term trend for Celldex Therapeutics's price / book?: Over 5 years (2020 to 2025), Celldex Therapeutics's price / book has grown at a -2.6% compound annual growth rate (CAGR), from 3.9× to 3.4×.
What does price / book mean?: Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.